港股通创新药ETF汇添富(159570)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-5,996,794,837.95 |
-1,627,137,027.69 |
1,094,680,110.91 |
-13,730,909.89 |
| 利息合计 |
4,266,293.97 |
5,007,818.94 |
1,026,890.24 |
421,793.31 |
| 其中:存款利息收入 |
4,266,293.97 |
5,007,818.94 |
1,026,890.24 |
421,793.31 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-1,978,028,572.35 |
723,544,578.10 |
76,334,739.31 |
-11,040,620.01 |
| 其中:股票投资收益 |
-2,052,818,160.16 |
654,878,768.20 |
65,353,060.89 |
-14,040,889.38 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
74,789,587.81 |
68,665,809.90 |
10,981,678.42 |
3,000,269.37 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-4,039,521,932.54 |
-2,480,665,696.30 |
977,543,223.86 |
-6,311,712.73 |
| 其他收入 |
16,489,372.97 |
124,976,271.57 |
39,775,257.50 |
3,199,629.54 |
| 费用 |
75,221,653.83 |
65,047,947.31 |
7,438,989.57 |
1,863,904.82 |
| 管理人报酬 |
61,811,611.02 |
53,381,016.85 |
6,054,585.90 |
1,439,005.61 |
| 基金托管费 |
12,362,322.13 |
10,676,203.40 |
1,210,917.21 |
287,801.07 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
1,047,720.68 |
990,727.06 |
173,486.46 |
137,098.14 |
| 利润总额 |
-6,072,016,491.78 |
-1,692,184,975.00 |
1,087,241,121.34 |
-15,594,814.71 |